Integrin αvβ3 as a Therapeutic Target for Blocking Tumor-Induced Angiogenesis
The DOI matches its Crossref record.
Abstract
The integrin receptor alphavbeta3 has been shown to play a critical role in several distinct processes, such as angiogenesis, osteoclast-mediated bone resorption and tumor metastasis. Its expression is upregulated in newly synthesized blood vessels produced in response to a variety of tumors and purified angiogenic factors. Studies show that alphavbeta3 is a critical target downstream from perhaps all angiogcnic factors. Proof-of-principle that alphavbeta3 antagonists such as monoclonal antibodies and small molecules block angiogenesis and tumor growth has been obtained in several animal models. Many endogenous inhibitors of angiogenesis such as angiostatin, endostatin and tumstatin seem to work through the alphavbeta3 receptor further emphasizing the critical role of this receptor in angiogenesis. In addition, the alphavbeta3 receptor has been clearly implicated in several pathological processes such as rheumatoid arthritis, osteoporosis, and metastasis of prostate cancer to bone. Thus alphavbeta3 may prove to be an important target for pharmacological intervention in more than one clinical setting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The critical nature of integrin binding to angiogenesis is also noted in other situations such as embryogenesis, where inhibition of b 1 integrins interfere with the development of the embryonic vasculature 63 and in oncology, where integrin inhibitors are employed to inhibit tumor angiogenesis.”
From Interactions between extracellular matrix and growth factors in wound healing (2009) · cites this paper as [64]
Citations
Cited by
Nicolas, J., Mura, S., Brambilla, D., Mackiewicz, N., & Couvreur, P. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35265f · Cited by 1,270
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis
Presta, M., Dell’Era, P., Mitola, S., Moroni, E., Ronca, R., & Rusnati, M. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.004 · Cited by 1,261
Interactions between extracellular matrix and growth factors in wound healing
Schultz, G. S., & Wysocki, A. (2009) · Wound Repair and Regeneration · doi:10.1111/j.1524-475x.2009.00466.x · Cited by 1,126
Angiogenesis as a Novel Component of Inflammatory Bowel Disease Pathogenesis
Danese, S., Sans, M., de la Motte, C., Graziani, C., West, G., Phillips, M. H., Pola, R., Rutella, S., Willis, J., Gasbarrini, A., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.03.054 · Cited by 374
In vivo Near-Infrared Fluorescence Imaging of Integrin αvβ3 in Brain Tumor Xenografts
Chen, X., Conti, P. S., & Moats, R. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1956 · Cited by 347
Liu, S. (2009) · Bioconjugate Chemistry · doi:10.1021/bc900167c · Cited by 344
Radiolabeled Multimeric Cyclic RGD Peptides as Integrin αvβ3Targeted Radiotracers for Tumor Imaging
Liu, S. (2006) · Molecular Pharmaceutics · doi:10.1021/mp060049x · Cited by 340
Wu, Y., Zhang, X., Xiong, Z., Cheng, Z., Fisher, D. R., Liu, S., Gambhir, S. S., & Chen, X. S. (2005) · PubMed · Cited by 325
Integrin αvβ3‐targeted cancer therapy
Liu, Z., Wang, F., & Chen, X. (2008) · Drug Development Research · doi:10.1002/ddr.20265 · Cited by 323
Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2.
Zhang, X., Xiong, Z., Wu, Y., Cai, W., Tseng, J. R., Gambhir, S. S., & Chen, X. S. (2006) · PubMed · Cited by 282
Chen, X. S., Hou, Y., Tohme, M. S., Park, R. J.-H., Khankaldyyan, V., Gonzales-Gomez, I., Bading, J. R., Laug, W. E., & Conti, P. S. (2004) · PubMed · Cited by 254
Cooperation between integrin ανβ3 and VEGFR2 in angiogenesis
Somanath, P. R., Malinin, N. L., & Byzova, T. V. (2009) · Angiogenesis · doi:10.1007/s10456-009-9141-9 · Cited by 254
Li, Z.-B., Cai, W., Cao, Q., Chen, K., Wu, Z., He, L., & Chen, X. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.039859 · Cited by 251
Leenders, W. P. J., Küsters, B., Verrijp, K., Maass, C., Wesseling, P., Heerschap, A., Ruiter, D., Ryan, A., & de Waal, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0823 · Cited by 231
In vitro cancer cell–ECM interactions inform in vivo cancer treatment
Holle, A. W., Young, J. L., & Spatz, J. P. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.007 · Cited by 213
Schnell, O., Krebs, B., Carlsen, J., Miederer, I., Goetz, C., Goldbrunner, R. H., Wester, H.-J., Haubner, R., Pöpperl, G., Holtmannspötter, M., et al. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-024 · Cited by 199
68Ga-labeled multimeric RGD peptides for microPET imaging of integrin αvβ3 expression
Li, Z.-B., Chen, K., & Chen, X. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0692-y · Cited by 190
Cai, W., Wu, Y., Chen, K., Cao, Q., Tice, D. A., & Chen, X. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1480 · Cited by 187
Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy
Upton, D. H., Ung, C., George, S. M., Tsoli, M., Kavallaris, M., & Ziegler, D. S. (2022) · Theranostics · doi:10.7150/thno.69682 · Cited by 182
CCL5 increases lung cancer migration via PI3K, Akt and NF-κB pathways
Huang, C.-Y., Fong, Y.-C., Lee, C.-Y., Chen, M.-Y., Tsai, H.-C., Hsu, H.-C., & Tang, C.-H. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.11.014 · Cited by 176
Integrin αβ3-Targeted Imaging of Lung Cancer
Chen, X., Sievers, E., Hou, Y., Park, R., Tohme, M., Bart, R., Bremner, R., Bading, J. R., & Conti, P. S. (2005) · Neoplasia · doi:10.1593/neo.04538 · Cited by 176
Integrins, CAFs and Mechanical Forces in the Progression of Cancer
Jang, I., & Beningo, K. (2019) · Cancers · doi:10.3390/cancers11050721 · Cited by 170
Integrin Signaling in Glioma Pathogenesis: From Biology to Therapy
Ellert-Miklaszewska, A., Poleszak, K., Pasierbinska, M., & Kaminska, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030888 · Cited by 163
Vrettos, E. I., Mező, G., & Tzakos, A. G. (2018) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.14.80 · Cited by 176
Cai, W., Zhang, X., Wu, Y., & Chen, X. S. (2006) · PubMed · Cited by 171
Radiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECT
Zhou, Y., Chakraborty, S., & Liu, S. (2011) · Theranostics · doi:10.7150/thno/v01p0058 · Cited by 149
Rybak, J., Ettorre, A., Kaissling, B., Giavazzi, R., Neri, D., & Elia, G. (2005) · Nature Methods · doi:10.1038/nmeth745 · Cited by 159
Rusnati, M., & Presta, M. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207781039689 · Cited by 141
The role of β3-integrins in tumor angiogenesis: context is everything
Robinson, S. D., & Hodivala‐Dilke, K. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2011.03.014 · Cited by 146
Angiogenesis blockade as a new therapeutic approach to experimental colitis
Danese, S., Sans, M., Spencer, D. M., Beck, I., Doñate, F., Plunkett, M. L., de la Motte, C., Redline, R., Shaw, D. E., Levine, A. D., et al. (2007) · Gut · doi:10.1136/gut.2006.114314 · Cited by 130
Alghisi, G. C., Ponsonnet, L., & Rüegg, C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004449 · Cited by 128
Peptide Receptor Radionuclide Therapy: An Overview
Dash, A., Chakraborty, S., Pillai, M. R. A., & Knapp, F. F. (. (2015) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2014.1741 · Cited by 128
Shi, J., Kim, Y., Zhai, S., Liu, Z., Chen, X. S., & Liu, S. (2009) · Bioconjugate Chemistry · doi:10.1021/bc800455p · Cited by 127
Albert, J. M., Cao, C., Geng, L., Leavitt, L., Hallahan, D. E., & Lu, J. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.04.036 · Cited by 125
Tumor-Selective Response to Antibody-Mediated Targeting of αvβ3 Integrin in Ovarian Cancer
Landen, C. N., Kim, T.-J., Lin, Y. G., Merritt, W. M., Kamat, A. A., Han, L. Y., Spannuth, W. A., Nick, A. M., Jennnings, N. B., Kinch, M. S., et al. (2008) · Neoplasia · doi:10.1593/neo.08740 · Cited by 120
Battle, M. R., Goggi, J., Allen, L., Barnett, J., & Morrison, M. S. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.077479 · Cited by 121
Oliveira‐Ferrer, L., Hauschild, J., Fiedler, W., Bokemeyer, C., Nippgen, J., Çeli̇k, İ., & Schuch, G. (2008) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-27-86 · Cited by 117
44Sc: An Attractive Isotope for Peptide-Based PET Imaging
Hernandez, R., Valdovinos, H. F., Yang, Y., Chakravarty, R., Hong, H., Barnhart, T. E., & Cai, W. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500343j · Cited by 116
Vallabhajosula, S., Sólnes, L. B., & Vallabhajosula, B. (2011) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2011.02.003 · Cited by 150
Shi, J., Wang, L., Kim, Y., Zhai, S., Liu, Z., Chen, X. S., & Liu, S. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm801134k · Cited by 109
Radiolabeled Cyclic RGD Peptide Bioconjugates as Radiotracers Targeting Multiple Integrins
Liu, S. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00327 · Cited by 122
Molecular modeling of the thyroid hormone interactions with αvβ3 integrin
Cody, V., Davis, P. J., & Davis, F. B. (2006) · Steroids · doi:10.1016/j.steroids.2006.11.008 · Cited by 122
RGD-dependent Binding of Procathepsin X to Integrin αvβ3 Mediates Cell-adhesive Properties
Lechner, A. M., Assfalg-Machleidt, I., Zahler, S., Stoeckelhuber, M., Machleidt, W., Jochum, M., & Nägler, D. K. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513439200 · Cited by 105
Cerebral arteriovenous malformations. Part 1: cellular and molecular biology
Moftakhar, P., Hauptman, J. S., Malkasian, D. R., & Martin, N. A. (2009) · Neurosurgical FOCUS · doi:10.3171/2009.2.focus09316 · Cited by 104
Near-Infrared Fluorescence Imaging of Tumor Integrin αvβ3 Expression with Cy7-Labeled RGD Multimers
Wu, Y., Cai, W., & Chen, X. S. (2006) · Molecular Imaging and Biology · doi:10.1007/s11307-006-0041-8 · Cited by 101
Direct targeting of αvβ3 integrin on tumor cells with a monoclonal antibody, Abegrin™
Mulgrew, K., Kinneer, K., Yao, X.-T., Ward, B. K., Damschroder, M. M., Walsh, B., Mao, S.-Y., Gao, C., Kiener, P. A., Coats, S., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0356 · Cited by 96
Biodegradable Polydepsipeptides
Feng, Y., & Guo, J. (2009) · International Journal of Molecular Sciences · doi:10.3390/ijms10020589 · Cited by 96
Wei, L., Ye, Y., Wadas, T. J., Lewis, J. S., Welch, M. J., Achilefu, S. A., & Anderson, C. J. (2009) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2008.12.008 · Cited by 95
Cyclic RGD-modified chitosan/graphene oxide polymers for drug delivery and cellular imaging
Wang, C., Chen, B., Zou, M., & Cheng, G. (2014) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2014.07.018 · Cited by 93
Xie, X., Hu, X., Li, Q., Yin, M., Song, H., Hu, J., Wang, L., Fan, C., & Chen, N. (2020) · Nano Letters · doi:10.1021/acs.nanolett.0c01503 · Cited by 95
One-step radiosynthesis of 18F-AlF-NOTA-RGD2 for tumor angiogenesis PET imaging
Liu, S., Liu, H., Jiang, H., Xu, Y., Zhang, H., & Cheng, Z. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1847-4 · Cited by 92
Carbon Dots in Biomedicine: A Review
Zhu, P., Wang, S., Zhang, Y., Li, Y., Liu, Y., Li, W., Wang, Y., Xiang, Y., & Luo, D. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c01215 · Cited by 91
Huang, C., Lee, C., Chen, M., Yang, W., Chen, Y., Chang, C., Hsu, H., Fong, Y., & Tang, C. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21846 · Cited by 97
Efficacy of systemic temozolomide‐activated phage‐targeted gene therapy in human glioblastoma
Przystal, J. M., Waramit, S., Pranjol, M. Z. I., Yan, W., Chu, G., Chongchai, A., Samarth, G., Olaciregui, N. G., Tabatabai, G., Carcaboso, A. M., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201708492 · Cited by 85
In Vivo Near-Infrared Fluorescence Imaging of Integrin αvβ3 in an Orthotopic Glioblastoma Model
Hsu, A. R., Hou, L. C., Veeravagu, A., Greve, J. M., Vogel, H. S., Tse, V., & Chen, X. S. (2006) · Molecular Imaging and Biology · doi:10.1007/s11307-006-0059-y · Cited by 84
Huang, Y., Hsiao, Y., Chen, Y., Wei, Y., Lai, T.-H., & Tang, C. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.08.025 · Cited by 88
Mondul, A. M., Weinstein, S. J., Bosworth, T., Remaley, A. T., Virtamo, J., & Albanes, D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047730 · Cited by 80
Radiolabeled cyclic RGD peptides as radiotracers for tumor imaging
Shi, J., Wang, F., & Liu, S. (2016) · Biophysics Reports · doi:10.1007/s41048-016-0021-8 · Cited by 84
Isoaspartate-dependent molecular switches for integrin–ligand recognition
Corti, A., & Curnis, F. (2011) · Journal of Cell Science · doi:10.1242/jcs.077172 · Cited by 83
Modulation of prostate cancer growth in bone microenvironments
Edlund, M., Sung, S., & Chung, L. W. K. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10702 · Cited by 95
Zheng, Y., Ji, S., Czerwiński, A. A., Valenzuela, F., Pennington, M. W., & Liu, S. (2014) · Bioconjugate Chemistry · doi:10.1021/bc500452y · Cited by 76
CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil
Nasiri, F., Kazemi, M., Mirarefin, S. M. J., Kancha, M. M., Najafabadi, M. A., Salem, F., Shokoohi, S. D., Bakhshi, S. E., Kozani, P. S., & Kozani, P. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1018786 · Cited by 81
Peptides for optical medical imaging and steps towards therapy
Staderini, M., Megía-Fernández, A., Dhaliwal, K., & Bradley, M. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.09.039 · Cited by 73
Targeting of peptide‐binding receptors on cancer cells with peptide‐drug conjugates
Worm, D. J., Els‐Heindl, S., & Beck‐Sickinger, A. G. (2020) · Peptide Science · doi:10.1002/pep2.24171 · Cited by 83
Therapeutic Targets of Multiple Angiogenic Factors for the Treatment of Cancer and Metastasis
Cao, Y., & Liu, Q. (2007) · Advances in cancer research · doi:10.1016/s0065-230x(06)97009-2 · Cited by 76
Lin, T., Tan, T., Tsai, T.-H., Chen, C., Hsieh, T., Lee, S., Liu, H.-H., Chen, W., & Tang, C. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14059790 · Cited by 71
Romero‐Gavilán, F., Araújo‐Gomes, N., Ródenas‐Rochina, J., Sánchez, A., Azkargorta, M., Iloro, I., Elortza, F., García‐Arnáez, I., Gurruchaga, M., Goñi, I., et al. (2016) · Biofouling · doi:10.1080/08927014.2016.1259414 · Cited by 75
Yeh, Y.-Y., Chiao, C.-C., Kuo, W.-Y., Hsiao, Y., Chen, Y., Wei, Y., Lai, T.-H., Fong, Y., & Tang, C. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.11.017 · Cited by 77
Gong, C., Stoletov, K. V., & Terman, B. I. (2004) · Angiogenesis · doi:10.1007/s10456-004-7960-2 · Cited by 65
Sawyer, T. K. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.1.1 · Cited by 69
Multimodality Tumor Imaging Targeting Integrin α v β 3
Cai, W., Gambhir, S. S., & Chen, X. S. (2005) · BioTechniques · doi:10.2144/000112091 · Cited by 65
Osteoblasts‐derived BMP‐2 enhances the motility of prostate cancer cells via activation of integrins
Lai, T., Fong, Y., Fu, W., Yang, R., & Tang, C. (2008) · The Prostate · doi:10.1002/pros.20799 · Cited by 71
Conjugates of Modified Cryptophycins and RGD-Peptides Enter Target Cells by Endocytosis
Nahrwold, M., Weiß, C., Bogner, T., Mertink, F., Conradi, J., Sammet, B., Palmisano, R., Gracia, S. R., Preuße, T., & Sewald, N. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301346z · Cited by 61
Rucci, N., Di Giacinto, C., Orrù, L., Millimaggi, D., Baron, R., & Teti, A. M. (2005) · Journal of Cell Science · doi:10.1242/jcs.02436 · Cited by 65
Hallak, L. K., Merchan, J. R., Storgard, C. M., Loftus, J. C., & Russell, S. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2879 · Cited by 61
Platelet-targeted pharmacologic treatments as anti-cancer therapy
Gresele, P., Momi, S., Malvestiti, M., & Sebastiano, M. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9679-8 · Cited by 61
Adenoviral vectors—How to use them in cancer gene therapy?
Majhen, D., & Ambriović‐Ristov, A. (2006) · Virus Research · doi:10.1016/j.virusres.2006.02.001 · Cited by 59
Gottschalk, K. (2005) · Structure · doi:10.1016/j.str.2005.02.014 · Cited by 62
Fong, Y., Hsu, S.-F., Wu, C.-L., Li, T., Kao, S.-T., Tsai, F., Chen, W., Liu, S., Wu, C.-M., & Tang, C. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.07.010 · Cited by 59
Nanomaterials for medical diagnosis and therapy
Kumar, C. S. S. R. (2007) · Cited by 71
Self-citationMorgan, M. R., Thomas, G. J., Russell, A. J., Hart, I. R., & Marshall, J. F. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401736200 · Cited by 56
Cell adhesive PET membranes by surface grafting of RGD peptidomimetics
Biltresse, S., Attolini, M. M., & Marchand‐Brynaert, J. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2004.11.042 · Cited by 55
Xiong, Z., Cheng, Z., Zhang, X., Patel, M., Wu, J. C., Gambhir, S. S., & Chen, X. S. (2006) · PubMed · Cited by 54
Lu, X., Lu, D., Scully, M. F., & Kakkar, V. V. (2008) · Perspectives in Medicinal Chemistry · doi:10.1177/1177391x0800200003 · Cited by 65
Response of Human Pancreatic Cancer Cell Xenografts to Tetraiodothyroacetic Acid Nanoparticles
Yalçın, M., Lin, H., Sudha, T., Bharali, D. J., Meng, R., Tang, H.-Y., Davis, F. B., Stain, S. C., Davis, P. J., & Mousa, S. A. (2013) · Hormones and Cancer · doi:10.1007/s12672-013-0137-y · Cited by 55
Tan, M., & Lu, Z. (2011) · Theranostics · doi:10.7150/thno/v01p0083 · Cited by 56
The disintegrin tzabcanin inhibits adhesion and migration in melanoma and lung cancer cells
Saviola, A. J., Burns, P. D., Mukherjee, A. K., & Mackessy, S. P. (2016) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2016.04.008 · Cited by 56
Short Peptides Interfering with Signaling Pathways as New Therapeutic Tools for Cancer Treatment
Ellert‐Miklaszewska, A., Poleszak, K., & Kaminska, B. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0189 · Cited by 54
Urbinati, C., Chiodelli, P., & Rusnati, M. (2008) · Molecules · doi:10.3390/molecules13112758 · Cited by 53
Preliminary Clinical Application of RGD-Containing Peptides as PET Radiotracers for Imaging Tumors
Li, L., Chen, X. S., Yu, J., & Yuan, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.837952 · Cited by 56
Cobb, D. A., de Rossi, J., Liu, L., An, E., & Lee, D. W. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003816 · Cited by 51
Wang, H., Wu, C., Wan, S., Zhang, H., Zhou, S., & Liu, G. (2013) · Toxicology · doi:10.1016/j.tox.2013.03.015 · Cited by 48
Chung, K. F. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.1.19 · Cited by 51
Control of melanoma progression by various matrikines from basement membrane macromolecules
Brassart‐Pasco, S., Ramont, L., Maquart, F., & Monboisse, J. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2003.09.006 · Cited by 49
Blocking αvβ3 integrin by a recombinant RGD disintegrin impairs VEGF signaling in endothelial cells
Montenegro, C. F., Pontes, C. L. S., Ribeiro, J. U., Machado, A. Z., Ramos, R. F., Figueiredo, C. C., Morandi, V., & Selistre-de-Araújo, H. S. (2012) · Biochimie · doi:10.1016/j.biochi.2012.04.020 · Cited by 59
Dort, M. V., Rehemtulla, A., & Ross, B. D. (2008) · Current Computer - Aided Drug Design · doi:10.2174/157340908783769265 · Cited by 49
Signaling and regulatory mechanisms of integrin ανβ6 on the apoptosis of colon cancer cells
Zhang, Z., Xu, K., He, Q., Wei-bo, N., Wang, J., Yue-tang, M., Jin-shen, W., Wang, G., Yang, G., & Niu, J. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.02.054 · Cited by 46
Extracellular Angiogenic Growth Factor Interactions: An Angiogenesis Interactome Survey
Rusnati, M., & Presta, M. (2006) · Endothelium · doi:10.1080/10623320600698011 · Cited by 50
Wu, C. T., Gong, F., Pang, P., Shen, M., Zhu, K., Cheng, D., Liu, Z., & Shan, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066416 · Cited by 44
Two 90Y-Labeled Multimeric RGD Peptides RGD4 and 3PRGD2 for Integrin Targeted Radionuclide Therapy
Liu, Z., Shi, J., Jia, B., Yu, Z., Liu, Y., Zhao, H., Li, F., Tian, J., Chen, X. S., Liu, S., et al. (2011) · Molecular Pharmaceutics · doi:10.1021/mp100403y · Cited by 43
Metadata
- Authors
- Kumar, C.
- Corresponding author
- Kumar, C.
- Venue
- Current Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2003-02-01
- Volume
- 4
- Issue
- 2
- Pages
- 123-131
- ISSN
- 1389-4501 (ISSN-L)
- OpenAlex
- W147592962
- Cited by
- 280
- References
- 0
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 4 · 2023: 6 · 2022: 14 · 2021: 4 · 2020: 9 · 2019: 11 · 2018: 8 · 2017: 9 · 2016: 8 · 2015: 11 · 2014: 11 · 2013: 20 · 2012: 20
- FWCI
- 10.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Drug Targets (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Cell Adhesion Molecules Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Keywords
- integrin αvβ3, tumor angiogenesis, angiogenesis inhibitors, monoclonal antibodies, small molecule antagonists, angiostatin, endostatin, tumstatin, tumor growth, metastasis, bone metastasis, osteoclast resorption, rheumatoid arthritis, osteoporosis, therapeutic target
- MeSH terms
- Animals, Humans, Neoplasms, Neovascularization, Pathologic, Drug Delivery Systems, Angiogenesis Inhibitors, Integrin alphaVbeta3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.